Diamidex works in the industrial microbiology market—a vital sector that underpins water safety, public health, and quality assurance in industries like food, beverage, pharmaceuticals, and utilities. The global market was valued at €6 billion in 2023 and is expected to grow to €12 billion by 2030, driven by stricter regulations, increasing health awareness, and the need for faster, more reliable testing methods.
Diamidex focuses on the high-growth segment of rapid microbiological methods for water control. Today, over 75% of the market still uses slow, traditional culture-based testing, which can take days to detect contamination. For global companies like Coca-Cola, this delay carries major risk: if a batch of products is contaminated with harmful bacteria and released to the market, it can lead to costly recalls, reputational damage, and lost revenue. That is why preventive, fast, and reliable testing is critical—they need to identify problems before products leave the factory. Diamidex offers exactly that: a unique technology that delivers faster results without compromising regulatory credibility.
Main competitors include Bio-Rad, or Thermofisher which offer PCR based tests. While these methods provide faster results, they often fall short in regulatory acceptance and typically cannot distinguish between live and dead microbes—missing the mark for applications that require precise detection of viable bacteria. In addition, these systems require highly skilled technicians and tightly controlled laboratory conditions to avoid cross-contamination. Their equipment is also costly to maintain, making them significantly more expensive than Diamidex. Diamidex stands out by combining the speed the industry demands with the accuracy and compliance of culture-based testing. Its six patent families protect the core technology and provide a strong competitive moat. Other competitors like IDEXX and Merck offer Enzyme-based tests. Even if these solutions are compliant with culture-based testing, time to results are longer than the one obtained with DIAMIDEX technology. Moreover, with a capacity of 500 analyses per day, Diamidex is the only company capable of meeting customer needs
With over 17,000 tests performed and trusted partnerships, Diamidex has a strong, defensible position. Barriers to entry such as regulatory trust, technical complexity, and long sales cycles provide a competitive edge and reinforce Diamidex’s leadership in this growing market.
